Stray Dog
EN中文
EN中文

Prices are Hyperliquid perpetual futures: contracts that track each stock and trade 24/7. They are not exchange prices and can differ from them, most of all while US markets are closed. Change is over 24 hours. For information only.

  • TSLA—
  • PLTR—
  • HIMS—
  • SPCX—
  • SOFI—
  • BTC—
…Loading prices
HIMS

Morningstar takes the bear side, with No Moat, a $23 fair value and FTC settlement costs hanging over the stock

Sources (4)

Morningstar has given HIMS a bearish reading that collides head-on with yesterday's bullish narrative. It kept its No Moat rating, a fair value of $23 (17% below the current price) and Very High uncertainty.

Read more

It sees the 29 Jul FTC lawsuit as a new legal overhang, warns of a more expensive settlement, and directly questions the credibility of management's path to profitability in 2027. Bulls and bears agree on the bottom line: the real verdict waits for the Q2 results on 10 Aug. The current price already reflects most of the peptide good news and the rebound, and the legal front keeps weighing on it.

Key evidence

  • Morningstar kept its No Moat rating and $23 fair value (about 17% below the current price)
  • Uncertainty rating set at Very High
  • It sees the 29 Jul FTC suit as a new legal overhang and warns it could lead to a more expensive settlement: the legal tail risk is not just fines but possibly a large one-off payout
  • Still plenty of question marks over execution and margins
  • Explicitly calls HIMS's long-term profit targets highly optimistic and does not find management's 2027 profit path credible
  • The shares jumped 8% on 30 Jul but still fell for the week, the 4th straight weekly decline
Show 4 more
  • Benzinga reported a 2.44% rise to $27.70 on 31 Jul (a technical bounce on a risk-on market tailwind, not a fundamental improvement)
  • Still down 26% from the early-July high of $37.57
  • The consensus price target has not budged ($31.43 on MarketBeat's measure), and the sell-side is still sitting on the fence with a mix of Buy, Hold and Sell
  • The bulls (Seeking Alpha) treat the FTC suit as a panic gift; Morningstar treats it as a concrete overhang of rising settlement costs

Catalysts to watch

  • 10 Aug Q2 results (in 10 days): when bulls and bears get their real answer
  • Progress of the FTC suit and the size of any settlement
  • Data to test execution and margins

Risks

  • FTC settlement costs higher than the market expects
  • The 2027 profit path falls apart
  • The No Moat verdict is borne out: no competitive moat
  • The peptide good news is already priced in, and the legal front keeps weighing on the shares
  • The 4-week losing streak is unbroken

Sources 4

  1. Morningstar analyst report: No Moat, $23 fair value
  2. Benzinga, 31 Jul report: +2.44% at $27.70
  3. MarketBeat consensus price target $31.43
  4. Seeking Alpha bullish article (the opposing view)

A brief is a lead for our research, not a verified conclusion or advice.